The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
The patients ended up dying.
( z1 end-up :ARG1 ( z2 patient ) :ARG2 ( z3 die :ARG1 z2 ) )